Evidence map›Paper›PMID 37341816›Full record

ReviewFamilial cancer2023

Cancer surveillance for transgender and gender diverse patients with Lynch syndrome: a practice resource of the Collaborative Group of the Americas on Inherited Gastrointestinal Cancer.

Rachel Hodan, Linda Rodgers-Fouche, Anu Chittenden, Mev Dominguez-Valentin, James Ferriss, Lauren Gima, Ole-Petter R Hamnvik, Gregory E Idos, Kevin Kline, Diane R Koeller and 7 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Familial cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 10 institutions in 2 countries.

Rachel Hodan *Cancer Genetics, Stanford Health Care and Department of Pediatrics (Genetics), Stanford University School of Medicine, Palo Alto, CA, USA. rhodan@stanfordhealthcare.org.ORCID 0000-0003-2887-4079
Linda Rodgers-Fouche *Center for Cancer Risk Assessment, Massachusetts General Hospital, Boston, MA, USA.ORCID 0000-0002-3956-5821
Anu Chittenden *Division of Cancer Genetics and Prevention, Dana Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0002-7037-3430
Mev Dominguez-ValentinDepartment of Tumor Biology, Institute of Cancer Research, The Norwegian Radium Hospital, Oslo, Norway.ORCID 0000-0001-7856-0057
James FerrissDepartment of Gynecology and Obstetrics, Kelly Gynecologic Oncology Service, Johns Hopkins School of Medicine, Baltimore, MD, USA.ORCID 0000-0002-2053-8604
Lauren GimaDivision of Clinical Cancer Genomics, City of Hope National Medical Center, Duarte, CA, USA.
Ole-Petter R HamnvikCenter for Transgender Health, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-3600-2628
Gregory E IdosDivision of Gastroenterology, City of Hope National Medical Center, Duarte, CA, USA.
Kevin KlineDepartment of Family Medicine and Community Health, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.ORCID 0009-0000-8592-0268
Diane R KoellerDivision of Cancer Genetics and Prevention, Dana Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0003-1217-9514
Jessica M LongDivision of Hematology and Oncology, University of Pennsylvania Health System, Philadelphia, PA, USA.ORCID 0000-0003-0382-7890
Danielle McKennaDivision of Hematology and Oncology, University of Pennsylvania Health System, Philadelphia, PA, USA.
Charles MullerDivision of Gastroenterology and Hepatology, Northwestern University, Chicago, IL, USA.
Maxton ThomanDepartment of Urology, Massachusetts General Hospital, Boston, MA, USA.
Anton WintnerDepartment of Urology, Massachusetts General Hospital, Boston, MA, USA.
Bronwyn S BedrickDepartment of Gynecology and Obstetrics, Johns Hopkins School of Medicine, Baltimore, MD, USA.ORCID 0000-0002-1933-5586
Collaborative Group of the Americas on Inherited Gastrointestinal Cancer
Massachusetts General Hospital · USCity Of Hope National Medical Center · USDana-Farber Cancer Institute · USJohns Hopkins University · USUniversity of Pennsylvania Health System · USBrigham and Women's Hospital · USNorthwestern University · USNorwegian Cancer Society · NOStanford Health Care · USUniversity of Pennsylvania · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Transgender and gender diverse (TGD) populations with hereditary cancer syndromes face unique obstacles to identifying and obtaining appropriate cancer surveillance and risk-reducing procedures. There is a lack of care provider knowledge about TGD health management. Lynch syndrome (LS) is one of the most common hereditary cancer syndromes, affecting an estimated 1 in 279 individuals. There are no clinical guidelines specific for TGD individuals with LS, highlighting a need to improve the quality of care for this population. There is an urgent need for cancer surveillance recommendations for TGD patients. This commentary provides recommendations for cancer surveillance, risk-reducing strategies, and genetic counseling considerations for TGD patients with LS.

Indexed as

Colorectal Neoplasms, Hereditary NonpolyposisTransgender PersonsFemaleGenetic CounselingHumansMaleCancerLynch syndromeManagementSurveillanceTransgender and gender diverse

Identifiers

PMID37341816
OpenAlexW4381469212

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.